Early Career Network – Member Spotlight Interview Dr Zoé Colombet Early Career Network – Member Spotlight Interview Dr Zoé Colombet ECN Spotlight
COMs Webinar – MASLD & Obesity: Mechanisms & Management – Tuesday 28th October 2025 at 12:30-13:30 CET COMs Webinar – MASLD & Obesity: Mechanisms & Management – Tuesday 28th October 2025 at 12:30-13:30 CET COMs, Education, Upcoming Events, Webinar
Watch – Press conference highlights including Semaglutide from Monday 13 May Watch – Press conference highlights including Semaglutide from Monday 13 May May 13, 2024 EASO Secretariat ECO ECO2024 Day Three Share with your network Share on Facebook Share on Twitter Share on Linkedin Share via Email
Early Career Network – Member Spotlight Interview Dr Zoé Colombet Early Career Network – Member Spotlight Interview Dr Zoé Colombet ECN Spotlight
COMs Webinar – MASLD & Obesity: Mechanisms & Management – Tuesday 28th October 2025 at 12:30-13:30 CET COMs Webinar – MASLD & Obesity: Mechanisms & Management – Tuesday 28th October 2025 at 12:30-13:30 CET COMs, Education, Upcoming Events, Webinar
Effect of sweeteners and sweetness enhancers on weight management and gut microbiota composition in individuals with overweight or obesity: the SWEET study Effect of sweeteners and sweetness enhancers on weight management and gut microbiota composition in individuals with overweight or obesity: the SWEET study EU Projects, Research
Understanding Obesity: More than Weight Understanding Obesity: More than Weight Education, Infographics, Research
BASORD is celebrating its 30th anniversary in 2025! BASORD is celebrating its 30th anniversary in 2025! Education, Member News
Pediatric Obesity Training Course: APTO Pediatric Obesity Training Course: APTO Childhood Obesity, Education
Italy Approves the First Law Recognizing Obesity as a Chronic Disease Italy Approves the First Law Recognizing Obesity as a Chronic Disease Member News, Policy
Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO) Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO) Research